Document is current
Any future updates will be listed below
-
Authors
Gandhi, Prafull S. https://orcid.org/0000-0001-7949-4899
Zivkovic, Minka https://orcid.org/0000-0003-4545-7939
Østergaard, Henrik
Bonde, Amalie C.
Elm, Torben
Løvgreen, Monika N.
Schluckebier, Gerd
Johansson, Eva https://orcid.org/0000-0001-9330-5169
Olsen, Ole H. https://orcid.org/0000-0003-1216-7521
Olsen, Eva H. N.
de Bus, Ian-Arris https://orcid.org/0000-0002-1061-8352
Bloem, Karien
Alskär, Oskar
Rea, Catherine J.
Bjørn, Søren E.
Schutgens, Roger E. https://orcid.org/0000-0002-2762-6033
Sørensen, Benny
Urbanus, Rolf T. https://orcid.org/0000-0002-1601-9393
Faber, Johan H.
-
Funding
Funding for this research was provided by:
Hemab Therapeutics ApS
- License Information
-
More Information
Article History
Received: 7 June 2023
Accepted: 19 December 2023
First Online: 8 February 2024
Competing interests
: P.S.G.: employee and shareholder of Hemab Therapeutics. M.Z.: no conflicts of interest. H.Ø.: employee and shareholder of Hemab Therapeutics. A.C.B.: employee and shareholder of Hemab Therapeutics. T.E.: employee and shareholder of Novo Nordisk. M.N.L.: employee and shareholder of Novo Nordisk. G.S.: employee and shareholder of Novo Nordisk. E.J.: employee and shareholder of Novo Nordisk. O.H.O.: received consultation fees from Hemab Therapeutics. E.H.N.O.: no conflicts of interest. I.-A.d.B.: employee of Sanquin Diagnostic Services. K.B.: employee of Sanquin Diagnostic Services. O.A.: received consultation fees from Hemab Therapeutics. C.J.R.: employee and shareholder of Hemab Therapeutics. S.E.B.: shareholder of Hemab Therapeutics. R.E.S.: the institution of R.E.S. has received speaker’s fees and/or research grants from Bayer, CSL Behring, Novartis, Novo Nordisk, Octapharma, Roche, Sobi and Takeda. B.S.: employee and shareholder of Hemab Therapeutics. R.T.U.: no conflicts of interest. J.H.F.: employee and shareholder of Hemab Therapeutics.
